To obtain the new subject treating agent useful for treating septicemia or septic shock by making the agent include an anti-interleukin-8 antibody as an active ingredient.
This septicemia-treating agent includes anti-interleukin-8 antibody (anti-IL-8 antibody) as an active ingredient. The anti-IL-8 antibody is preferably a monoclonal antibody derived from a mammal, especially WS-4 antibody. The monoclonal antibody is obtained by immunizing an animal by using IL-8 as a sensitizing antibody, performing cell-fusion of the obtained immunized cells with myeloma cells as parent cells, further screening and cloning the obtained hybridoma and culturing the screened and cloned hybridoma. The WS-4 antibody is obtained from Mouse hybridoma WS-4 (FERM BP-5507). The objective treating agent can be orally administered and the effective divided dose thereof is, for example, 0.001-1,000mg/kg.
WAKABAYASHI TAKESHI
MATSUSHIMA TSUNAHARU
